Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.66 |
| ▸ | HINT1 | P49773 | 2/20 | 0.59 |
| ▸ | NT5E | P21589 | 2/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.56 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15336916 | 1.00 | ADORA3 (0.66) | ADORA3HINT1NT5EADORA2AADORA2B | |
| SCHEMBL27418170 | 1.00 | ADORA3 (0.66) | ADORA3HINT1NT5EADORA2AADORA2B | |
| SCHEMBL15958586 | 1.00 | ADORA3 (0.66) | ADORA3HINT1NT5EADORA2AADORA2B | |
| SCHEMBL24264307 | 0.92 | ADORA3 (0.66) | ADORA3HINT1NT5EADORA2AADORA2B | |
| SCHEMBL21418866 | 0.90 | ADORA2A (0.66) | ADORA3NT5EADORA2AADORA2BADORA1 | |
| SCHEMBL29100475 | 0.90 | ADORA2A (0.66) | ADORA3NT5EADORA2AADORA2BADORA1 | |
| SCHEMBL30601880 | 0.90 | ADORA2A (0.66) | ADORA3NT5EADORA2AADORA2BADORA1 | |
| SCHEMBL8624075 | 0.90 | ADORA2A (0.66) | ADORA3NT5EADORA2AADORA2BADORA1 | |
| SCHEMBL8624065 | 0.90 | ADORA2A (0.66) | ADORA3NT5EADORA2AADORA2BADORA1 | |
| SCHEMBL30601881 | 0.90 | ADORA2A (0.66) | ADORA3NT5EADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393935-A1 | METHOD FOR PRODUCING 2?-MODIFIED GUANOSINE COMPOUND | Nissan Chemical Corporation (JP) | 2024-07-03 | — | — | EP | disclosed |
| US-20120128760-A1 | LIPID COMPOSITIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20110256175-A1 | AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120128760-A1 | LIPID COMPOSITIONS | SGMS1, SGMS2, LIPA | ADORA3 4535/4885HINT1 3826/4885NT5E 4108/4885 |
| US-20110256175-A1 | AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | NSUN3, SARNP, LDLR | ADORA3 1308/4885HINT1 3565/4885NT5E 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.